| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFI44 |
| Uniprot No | Q8TCB0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-444aa |
| 氨基酸序列 | MAVTTRLTRLHEKILQNHFGGKRLSLLYKGSVHGFRNGVLLDRCCNQGPTLTVIYSEDHIIGAYAEESYQEGKYASIILFALQDTKISEWKLGLCTPETLFCCDVTKYNSPTNFQIDGRNRKVIMDLKTMENLGLAQNCTISIQDYEVFRCEDSLDERKIKGVIELRKSLLSALRTYEPYGSLVQQIRILLLGPIGAGKSSFFNSVRSVFQGHVTHQALVGTNTTGISEKYRTYSIRDGKDGKYLPFILCDSLGLSEKEGGLCRDDIFYILNGNIRDRYQFNPMESIKLNHHDYIDSPSLKDRIHCVAFVFDASSIQYFSSQMIVKIKRIRRELVNAGVVHVALLTHVDSMDLITKGDLIEIERCEPVRSKLEEVQRKLGFALSDISVVSNYSSEWELDPVKDVLILSALRRMLWAADDFLEDLPFEQIGNLREEIINCAQGKK |
| 分子量 | 74.58 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IFI44蛋白的示例参考文献(内容为模拟概括，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"IFI44 is an antiviral effector that promotes RIG-I signaling through interaction with the CARD domain"*
**作者**: Li, Y., et al.
**摘要**: 该研究揭示了重组人IFI44蛋白通过与RIG-I的CARD结构域相互作用，增强宿主抗病毒免疫反应，促进I型干扰素信号通路的激活。实验表明，IFI44敲除会显著抑制病毒诱导的干扰素产生。
---
2. **文献名称**: *"Interferon-induced protein 44 (IFI44) regulates hepatitis C virus replication"*
**作者**: Zhang, X., et al.
**摘要**: 本文发现重组IFI44蛋白在丙型肝炎病毒(HCV)感染中通过抑制病毒RNA复制发挥抗病毒作用。作者利用siRNA敲低和过表达实验验证了IFI44对HCV复制的调控机制。
---
3. **文献名称**: *"IFI44 as a potential biomarker for systemic lupus erythematosus activity"*
**作者**: Wang, L., et al.
**摘要**: 研究通过检测SLE患者血清中的重组IFI44蛋白水平，发现其表达与疾病活动度呈正相关，提示IFI44可能作为评估红斑狼疮严重程度的新型生物标志物。
---
4. **文献名称**: *"Structural and functional analysis of human IFI44 protein"*
**作者**: Smith, J., & Kumar, S.
**摘要**: 该文献解析了重组人IFI44蛋白的晶体结构，揭示了其N端结构域在结合核酸及调控先天免疫信号通路中的关键作用，为靶向IFI44的药物设计奠定基础。
---
**建议**：可通过PubMed或Google Scholar以关键词“IFI44 protein recombinant”或“human IFI44 function”检索最新文献。
Recombinant human IFI44 protein is a genetically engineered version of the interferon-induced protein 44 (IFI44), which plays a critical role in the innate immune response. IFI44 is encoded by the ISG (interferon-stimulated gene) family and is predominantly induced by type I interferons (IFN-α/β) during viral infections. First identified in the early 2000s, it is part of the host’s defense mechanism against pathogens, particularly viruses like hepatitis C virus (HCV) and influenza. The protein’s expression is tightly regulated, with elevated levels observed in viral infections, autoimmune disorders (e.g., lupus), and certain cancers.
Structurally, IFI44 contains conserved domains associated with nucleotide binding and enzymatic activity, though its exact biochemical mechanism remains under investigation. Studies suggest it may inhibit viral replication by interacting with viral components or modulating signaling pathways like the JAK-STAT cascade. Recombinant IFI44 is produced using expression systems (e.g., E. coli or mammalian cells) for functional studies, enabling researchers to explore its antiviral properties, immunomodulatory roles, and potential therapeutic applications. Recent research highlights its relevance in COVID-19 pathology, where dysregulated IFI44 expression correlates with disease severity. Its recombinant form serves as a vital tool for diagnostics, drug development, and understanding interferon-driven immune responses.
×
